Skip to main content
SpringerLink
Log in

Effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate on some proteins related to haemostasis in prostatic carcinoma patients

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Twenty-four previously untreated patients with carcinoma of the prostate were prospectively randomized to one of the following treatments: (1) ethinyl oestradiol combined with polyoestradiol phosphate (EE/EP); (2) estramustine phosphate (EM); (3) bilateral orchiectomy. The effects on some plasma proteins related to haemostasis were studied by measuring the concentrations of alpha-1-antitrypsin, orosmmucoid, haptoglobin, antithrombin III, C1-inhibitor and von Willebrand’s factor before and 3 months after the start of treatment. Orchiectomy induced a reduction of alpha-1-antitrypsin and haptoglobin, while the other studied proteins were unaffected. It was found that both EE/EP and EM treatment induced significant decreases of orosomucoid, haptoglobin, antithrombin III and C1-inhibitor, while the same treatment increased the plasma concentration of alpha-1-antitrypsin. None of these treatments showed any influence on the plasma concentration of the von Willebrand factor. No differences were observed between EE/EP and EM for any of the studied proteins, suggesting comparable oestrogenic effects of these forms of treatment in patients with prostatic carcinoma. The findings are discussed in relation to the proposed difference in thromboembolic complications between EE/EP and EM treatments of prostatic carcinoma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Veterans Administration’s Cooperative Urological Research Group. Carcinoma of the prostate: Treatment comparison.J. Urol., 98, 516 (1967).

    Google Scholar 

  2. Bailar, J. C., Byar, D. P.: Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo.Cancer, 26, 257 (1970).

    Article  PubMed  Google Scholar 

  3. Hedlund, P. O., Gustafson, H., Sjögren, S.: Cardiovascular complications to treatment of prostate cancer with estramustine phosphate or conventional estrogen.Scand. J. Urol. Nephrol., 55, 103 (1980).

    CAS  Google Scholar 

  4. Büller, H. R., Boon, T. A., Henny, C. P., Dabhoiwala, N. F., Ten Cate J. W.: Estrogen-induced deficiency and decrease in antithrombin III activity in patients with prostatic cancer.J. Urol., 128, 72 (1982).

    PubMed  Google Scholar 

  5. Agardh, C.-D., Nilsson-Ehle, P., Lundgren, R., Gustavsson, A.: The influence of treatment with estrogens and estramustine phosphate on platelet aggregation and plasma lipoproteins in non-disseminated prostatic carcinoma.J. Urol., 132, 1021 (1984).

    PubMed  CAS  Google Scholar 

  6. Glashan, R. W., Robinson, M. R. G.: Cardiovascular complications in the treatment of prostatic carcinoma.Br. J. Urol., 53, 624 (1981).

    PubMed  CAS  Google Scholar 

  7. Andersson, S. B., Gunnarsson, P. O., Nilsson, T.: Metabolism of estramustin phosphate (Estracyt) in patients with prostatic carcinoma.Eur. J. Drug. Metab. Pharmacokinet., 6, 149 (1981).

    Article  PubMed  CAS  Google Scholar 

  8. Daehlin, L., Damber, J-E, von Schoultz, B., Bergman, B.: The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in prostatic carcinoma patients.Br. J. Urol., 58, 412 (1986).

    Article  PubMed  CAS  Google Scholar 

  9. Laurell, C. B.: Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.Anal. Biochem., 15, 45 (1966).

    Article  PubMed  CAS  Google Scholar 

  10. Ahlgren, J. D.: Estramustine—current status 1983.Semin. Oncol., 10, 46 (1983).

    PubMed  CAS  Google Scholar 

  11. Bush, T. L., Barrett-Connor, E.: Noncontraceptive estrogen use and cardiovascular disease.Epidemiol Rev., 7, 80 (1985).

    Google Scholar 

  12. Gordon, E. M., Ratnoff, O. D., Saito, H., Donaldson, V. H., Pensky, J., Jones, P. K.: Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitors in women taking oral contraceptives.J. Lab. Clin. Med., 96, 762 (1980).

    PubMed  CAS  Google Scholar 

  13. Kok, P., Nilsson, T.: Assay characteristics and fibrin affinity of plasminogen activators of the intrinsic fibrinolytic system.Thromb. Res., 41, 197 (1986).

    Article  PubMed  CAS  Google Scholar 

  14. Nilsson, T., Bäck, O.: Elevated plasmin-antiplasmin complex levels in hereditary angioedema: evidence for the in vivo efficiency of the intrinsic fibrinolytic system.Thromb. Res., 40, 817 (1985).

    Article  PubMed  CAS  Google Scholar 

  15. Henriksson, P.: Cardiovascular and metabolic effects of exogenous estrogen in patients with prostatic cancer. Thesis. Kongl. Carolinska Medico Chirurgiska Institutet. Huddinge 1986.

    Google Scholar 

  16. Varenhorst, E., Risberg, B.: Effects of estrogen, orchidectomy, and cyproterone acetate on tissue fibrinolysis in patients with carcinoma of the prostate.Invest. Urol., 18, 355 (1981).

    PubMed  CAS  Google Scholar 

  17. Nilsson, T. K., Tomic, R., Ljungberg, B.: Effects of high dose MPA treatment on antithrombin III and other plasma proteins in males with renal or prostatic carcinoma.Scand. J. Urol. Nephrol., 23, 11 (1989).

    PubMed  CAS  Google Scholar 

  18. Siegel, S.: Non-parametric Statistics for the Behavioural Sciences. McGraw-Hill Kogakusha Ltd., Tokyo, 1956.

    Google Scholar 

  19. Henny, C. P., ten Cate H., Dabhoiwala, N. F., Buller, H. R., ten Cate J. W.: Effect of hormonal manipulation on antithrombin III activity in patients with prostatic carcinoma.Eur. Urol., 10, 202 (1984).

    PubMed  CAS  Google Scholar 

  20. Varenhorst, E., Wallentin, L., Risberg, B.: The effects of orchiectomy, oestrogens and cyproterone-acetate on the antithrombin concentration in carcinoma of the prostate.Urol. Res., 9, 25 (1981).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Urology and Andrology, Physiology and Clinical Chemistry, University of Umeå, Umeå, Sweden

    J. -E. Damber, L. Daehlin, R. Tomic & T. K. Nilsson

Authors
  1. J. -E. Damber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Daehlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Tomic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. K. Nilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Damber, J.E., Daehlin, L., Tomic, R. et al. Effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate on some proteins related to haemostasis in prostatic carcinoma patients. International Urology and Nephrology 23, 251–256 (1991). https://doi.org/10.1007/BF02550420

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02550420

Keywords

Search

Navigation